Business Description
Evotec SE
NAICS : 325412
SIC : 2834
ISIN : DE0005664809
Share Class Description:
FRA:EVT: Ordinary SharesCompare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USA1EVT.ItalyEVT.AustriaEVT.Bulgaria IPO Date
1999-11-10Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.81 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -2.45 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.64 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.7 | |||||
| 3-Year EBITDA Growth Rate | -38.6 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.66 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.82 | |||||
| 9-Day RSI | 60.98 | |||||
| 14-Day RSI | 61.17 | |||||
| 6-1 Month Momentum % | -38.92 | |||||
| 12-1 Month Momentum % | -66.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.09 | |||||
| Quick Ratio | 1.99 | |||||
| Cash Ratio | 1.13 | |||||
| Days Inventory | 18.26 | |||||
| Days Sales Outstanding | 53.2 | |||||
| Days Payable | 53.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -0.12 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 13.7 | |||||
| Operating Margin % | -12.7 | |||||
| Net Margin % | -22.05 | |||||
| FCF Margin % | -26.93 | |||||
| ROE % | -16.02 | |||||
| ROA % | -8 | |||||
| ROIC % | -5.11 | |||||
| 3-Year ROIIC % | -8.06 | |||||
| ROC (Joel Greenblatt) % | -23.78 | |||||
| ROCE % | -11.05 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 299.09 | |||||
| Shiller PE Ratio | 104.83 | |||||
| PS Ratio | 1.74 | |||||
| PB Ratio | 1.4 | |||||
| Price-to-Tangible-Book | 2.02 | |||||
| EV-to-EBIT | -7.55 | |||||
| EV-to-Forward-EBIT | -38.05 | |||||
| EV-to-EBITDA | -7.55 | |||||
| EV-to-Forward-EBITDA | 25.81 | |||||
| EV-to-Revenue | 1.86 | |||||
| EV-to-Forward-Revenue | 1.55 | |||||
| EV-to-FCF | -6.92 | |||||
| Price-to-Projected-FCF | 5.14 | |||||
| Price-to-Median-PS-Value | 0.26 | |||||
| Earnings Yield (Greenblatt) % | -13.25 | |||||
| FCF Yield % | -15.44 | |||||
| Forward Rate of Return (Yacktman) % | 23.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 777.052 | ||
| EPS (TTM) (€) | -0.971 | ||
| Beta | 1.18 | ||
| Volatility % | 58.05 | ||
| 14-Day RSI | 61.17 | ||
| 14-Day ATR (€) | 0.491384 | ||
| 20-Day SMA (€) | 6.601 | ||
| 12-1 Month Momentum % | -66.02 | ||
| 52-Week Range (€) | 5.115 - 21.7 | ||
| Shares Outstanding (Mil) | 177.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evotec SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evotec SE Frequently Asked Questions
What is Evotec SE(FRA:EVT)'s stock price today?
The current price of FRA:EVT is €7.71. The 52 week high of FRA:EVT is €21.70 and 52 week low is €5.12.
When is next earnings date of Evotec SE(FRA:EVT)?
The next earnings date of Evotec SE(FRA:EVT) is 2025-02-06 Est..
Does Evotec SE(FRA:EVT) pay dividends? If so, how much?
Evotec SE(FRA:EVT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers